GENZYME COMPLETES PURCHASE OF SYNVISC SALES AND MARKETING RIGHTS

Genzyme has completed the transaction to buy back the sales and marketing rights to Synvisc (hylan G-F 20) in the U.S. and five European countries from Wyeth. The cash transaction is accretive to Genzyme. Genzyme will now record all Synvisc end-user revenue in the U.S. and five European countries (Germany, Poland, Greece, Portugal and the Czech Republic). Synvisc is the leading viscosupplementation product for the treatment of pain due to osteoarthritis of the knee in the U.S. and Canada, and one of the top products in this category in Europe.

Boston dBusiness News (http://boston.dbusinessnews.com/shownews.php?type_news=latest&newsid=7033)